Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune response. Treatment targeting this immune response might be beneficial but there is limited evidence on its efficacy. The aim of this study was to determine if early treatment of patients with COVID-19 pneumonia with tocilizumab and/or steroids was associated with better outcome.
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
Mikulska, Malgorzata;Nicolini, Laura Ambra;Signori, Alessio;Di Biagio, Antonio;Sepulcri, Chiara;Russo, Chiara;Dettori, Silvia;Berruti, Marco;Sormani, Maria Pia;Giacobbe, Daniele Roberto;Vena, Antonio;De Maria, Andrea;Dentone, Chiara;Taramasso, Lucia;Mirabella, Michele;Magnasco, Laura;Mora, Sara;Delfino, Emanuele;Balletto, Elisa;Baldi, Federico;Briano, Federica;Ferrazin, Antonio;Labate, Laura;Mazzarello, Giovanni;Pincino, Rachele;Tutino, Stefania;Barisione, Emanuela;Bruzzone, Bianca;Orsi, Andrea;Schenone, Eva;Pelosi, Paolo;Beltramini, Sabrina;Giacomini, Mauro;Icardi, Giancarlo;Gratarola, Angelo;Bassetti, Matteo
2020-01-01
Abstract
Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune response. Treatment targeting this immune response might be beneficial but there is limited evidence on its efficacy. The aim of this study was to determine if early treatment of patients with COVID-19 pneumonia with tocilizumab and/or steroids was associated with better outcome.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
